Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have given their written consent to participate (or whose legal representative has done so on their behalf)
• People who agree to allow stored tumour tissue samples from their diagnosis to be used in the study (exceptions may be possible with approval from the lead researcher if samples are not available)
• People aged 18 or older
• People who are reasonably functional in daily life, as measured by a standard medical scale called the Karnofsky Performance Status, with a score of 60 or above (confirm with trial site)
• People who have a confirmed diagnosis of a type of returning or treatment-resistant B-cell lymphoma — specifically diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (tFL), or double-hit lymphoma (DHL) — and who are scheduled to receive a commercial CAR T-cell therapy called YESCARTA®
• People who have recovered from most side effects of previous cancer treatments (hair loss is an exception) before joining
• People who have been exposed to certain powerful broad-spectrum antibiotics within the 90 days before giving consent — including specific groups of antibiotics used to treat serious infections (confirm with trial site for the specific antibiotic list)
• People whose blood test results and organ function meet the standard requirements for CAR T patients at City of Hope, tested within 30 days before a procedure called leukapheresis (a process to collect immune cells)
• People who test negative for HIV, hepatitis C, and active hepatitis B — though people living with HIV who are on effective treatment with no detectable virus in the past 6 months may still meet this criterion
• People who meet other required infection screening tests, carried out within 28 days before the first day of treatment
• Women who could become pregnant must have a negative pregnancy test before joining
• People of childbearing potential who agree to use effective contraception or avoid heterosexual activity throughout the study and for at least 12 months after the last treatment

Who may not be able to join:

• People who have had major surgery in the 4 months before enrolling
• People who have received a live vaccine within 30 days before enrolling
• People who are unable to swallow capsules, or who have a condition that makes swallowing the study capsules (called FMT capsules) unsafe or impossible
• People with a history of inflammatory bowel disease or irritable bowel disorder
• People with severe food allergies
• People with a history of long-term or recurring accidental breathing in of food or liquid (chronic aspiration)
• People with a history of behavioural or substance use disorders that, in the lead researcher's judgement, could interfere with safely completing the study
• People with a history of conditions affecting memory or thinking that, in the lead researcher's judgement, could interfere with safely completing the study
• People with a diagnosis of a primary immune deficiency condition
• People with another active cancer requiring treatment, with some exceptions for certain non-aggressive cancers that do not need treatment (confirm with trial site)
• People with an active, uncontrolled bacterial, fungal, or viral infection that requires intravenous (IV) antibiotics or antifungal/antiviral medicines
• People whose test results or clinical findings, in the lead researcher's judgement, could make study participation unsafe
• People with any other condition that, in the investigator's judgement, raises safety concerns about participation
• People who, in the investigator's opinion, may not be able to follow all study procedures or attend all required appointments

Important: Always verify eligibility with the trial site directly before applying.